NCT06929299View on ClinicalTrials.gov

A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 12, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Primary Immune Thrombocytopenia (ITP)
Interventions
DRUG

STSA-1301 subcutaneous injection

Subjects will receive the STSA-1301 on the dates specified in the protocol

DRUG

Placebo

Subjects will receive the placebo on the dates specified in the protocol

Trial Locations (7)

101109

RECRUITING

Peking University People's Hospital, Beijing

233000

NOT_YET_RECRUITING

The First Affiliated Hospital of Bengbu Medical College, Bengbu

300020

NOT_YET_RECRUITING

Hospital of Hematology, Chinese Academy of Medical Sciences, Tianjin

330000

NOT_YET_RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

475000

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

710000

NOT_YET_RECRUITING

Xi'an Central Hospital, Xi’an

063000

NOT_YET_RECRUITING

North China University of Science and Technology Affiliated Hospital, Tangshan

All Listed Sponsors
lead

Jiangsu BioJeTay Biotechnology Co., Ltd.

INDUSTRY